NCT07033858 Evaluaion the Short Term Effects of Advograf Plus Rapamiune After Kidney Transplantation
| NCT ID | NCT07033858 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shahid Beheshti University of Medical Sciences |
| Condition | Kidney Transplant; Complications |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2025-03-01 |
| Primary Completion | 2026-03-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2025-03-01 with a primary completion date of 2026-03-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Cornerstone immunosuppressive therapy currently relies on immediate-release tacrolimus, a calcineurin inhibitor (CNI) that is potentially nephrotoxic and is more diabetogenic than cyclosporine A. A new formulation of tacrolimus has been launched: an extended-release formulation (Advagraf®/Astagraf XL®, Astellas company).
Eligibility Criteria
Inclusion Criteria: * All Kidney transplant recipients Exclusion Criteria: * Kidney-Pancreas transplant BMI\>30 cPRA\>0%
Contact & Investigator
Dalili
PRINCIPAL INVESTIGATOR
SBMU
Frequently Asked Questions
Who can join the NCT07033858 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Kidney Transplant; Complications. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07033858 currently recruiting?
Yes, NCT07033858 is actively recruiting participants. Contact the research team at dr.nooshindalili@gmail.com for enrollment information.
Where is the NCT07033858 trial being conducted?
This trial is being conducted at Tehran, Iran.
Who is sponsoring the NCT07033858 clinical trial?
NCT07033858 is sponsored by Shahid Beheshti University of Medical Sciences. The principal investigator is Dalili at SBMU. The trial plans to enroll 50 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.